CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
CAR-T 细胞治疗恶性肿瘤中的严重不良事件及应对策略
英文原题：Serious adverse events and coping strategies of CAR-T cells in the treatment of malignant tumors.
查看英文原题
Serious adverse events and coping strategies of CAR-T cells in the treatment of malignant tumors.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
CAR-T（CAR-T）细胞技术已成功用于治疗B细胞来源的血液系统肿瘤和多发性骨髓瘤。CAR-T 细胞也在多种实体瘤中开展研究。目前关于CAR-T 细胞治疗恶性肿瘤的临床报道较多。CAR-T 细胞的杀瘤活性及CAR-T 细胞特有的不良反应已被多项研究证实。有证据表明，严重不良事件可危及生命。CAR-T 细胞治疗在临床中的应用日益广泛，因此重视其严重不良事件十分重要。在本综述中，我们通过阅读文献和检索相关临床研究，总结了CAR-T 细胞治疗恶性肿瘤的严重不良事件，并讨论了严重不良事件的管理与治疗，以期为处理此类患者的临床医生提供理论支持。
展开英文摘要原文
Chimeric antigen receptor T (CAR-T) cells technology has been successfully used in the treatment of B cell-derived hematological tumors and multiple myeloma. CAR-T cells are also being studied in a variety of solid tumors. Current clinical reports on CAR-T cells in the treatment of malignant tumors are abundant. The tumor-killing activity of CAR-T cells and the unique adverse effects of CAR-T cells have been confirmed by many studies. There is evidence that serious adverse events can be life-threatening.
CAR-T cells therapy is increasingly used in clinical settings, so it is important to pay attention to its serious adverse events. In this review, we summarized the serious adverse events of CAR-T cells in the treatment of malignant tumors by reading literature and searching relevant clinical studies, and discussed the management and treatment of serious adverse events in an effort to provide theoretical support for clinicians who deal with such patients.
论文信息
- 作者
- Chen X、Li P、Tian B、Kang X
- 单位
- Department of Orthopedics, Honghui Hospital, Xi'an Jiaotong University, Xi'an, China.China
- 文献类型
- 综述
- 期刊
- Frontiers in immunology2022
- 原文标识
- PubMed 36569917 · DOI 10.3389/fimmu.2022.1079181
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →